Correction to: Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin
- PMID: 29856063
- PMCID: PMC5999159
- DOI: 10.1007/s40273-018-0676-8
Correction to: Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin
Abstract
The article Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin written by Guy Neff, Woodie Zachry was originally published electronically on the publisher's internet portal (currently Springer Link) on April 12, 2018 without open access.
Erratum for
-
Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin.Pharmacoeconomics. 2018 Jul;36(7):809-822. doi: 10.1007/s40273-018-0641-6. Pharmacoeconomics. 2018. PMID: 29651649 Free PMC article.
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
